Recombinant Humanized Monoclonal Antibody MIL93

Small molecule

Recombinant Humanized Monoclonal Antibody MIL93 is one of 59 small molecule programs targeting Lymphoma. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

LymphomaActive, not recruiting

Lupus NephritisActive, not recruiting

LymphomaPhase 1/Phase 2

Active, not recruiting

Lupus NephritisPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

1774 competitors in Lymphoma

#DrugCompanyPhaseTrials

Oncaspar

SServier

Preclinical

15 2

Zofran

Novartis

Preclinical

2 3

Wellcovorin

GGlaxo Dba Glaxosmithkline

Preclinical

4 4

Tafasitamab

Incyte

Preclinical

7 5

Kenalog

BBausch Health Americas, Inc.

Preclinical

1 6

Elitek

AAzienda U.S.L. 1 di Massa e Carrara

Systemic Therapy

1 8

CAR-T

HHebei Senlang Biotechnology Inc., Ltd.

Preclinical

3 9

Rhg-CSF

CCSPC Baike (Shandong) Biopharmaceutical Co., Ltd.

Preclinical

3 10

JY231

SShenzhen Genocury Biotech Co., Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Lymphoma3 trials

MIL62 Plus Lenalidomide for Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (FL and MZL)

Recruiting·BBeijing Mabworks Biotech Co., Ltd.·Phase 1/2·NCT04110301·53 enrolled

A Study of MIL62 in Treatment of CD20 Positive B-cell Lymphomas

Completed·BBeijing Mabworks Biotech Co., Ltd.·Phase 1·NCT04103905·27 enrolled

A Study of MIL62 Combined With Orelabrutinib for the Treatment of R/R CD20+B Cell Lymphoma

Unknown status·BBeijing InnoCare Pharma Tech Co., Ltd.·Phase 1/2·NCT04304040·43 enrolled

Advanced Malignancies1 trial

A Clinical Study of MIL95 in Advanced Malignancies.

Recruiting·BBeijing Mabworks Biotech Co., Ltd.·Phase 1·NCT04651348·58 enrolled

Recurrent or Metastatic1 trial

Phase I Clinical Study of MBS301 in Treatment of HER2 Positive Recurrent or Metastatic Malignant Solid Tumor

Recruiting·BBeijing Mabworks Biotech Co., Ltd.·Phase 1·NCT03842085·34 enrolled

Lupus Nephritis1 trial

Evaluation of the Tolerance, Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of MIL62 Injection for Treating Lupus Nephritis

Active, not recruiting·BBeijing Mabworks Biotech Co., Ltd.·Phase 1/2·NCT07044115·41 enrolled

Solid Tumors1 trial

A Clinical Study of MIL93 in Solid Tumors.

Unknown status·BBeijing Mabworks Biotech Co., Ltd.·Phase 1·NCT04671875·228 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for Recombinant Humanized Monoclonal Antibody MIL93. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Recombinant Humanized Monoclonal Antibody MIL93 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Recombinant Humanized Monoclonal Antibody MIL93. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Beijing Mabworks Biotech Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: BBeijing Mabworks Biotech Co., Ltd.

Recombinant Humanized Monoclonal Antibody MIL93

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Lymphoma3 trials

Advanced Malignancies1 trial

Recurrent or Metastatic1 trial

Lupus Nephritis1 trial

Solid Tumors1 trial

References

Drug Info

Quick Facts

Related News